Cancer Immunotherapy Guidelines Immune Effector Cell-Related Adverse Events Subcommittee

SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of consensus statements developed by experts in the treatment of specific types of cancer. Each consensus statement provides key indicators to help practicing oncologists determine when and how to best use immunotherapy to treat their patients. These systematically developed recommendations promote enhanced clinical decisions concerning patient selection, toxicity management, clinical endpoints, and the sequencing or combination of therapies. The Immune Effector Cell-Related Adverse Events Subcommittee was developed to generate consensus statements pertaining to management of toxicities associated with immune effector cell therapies.

Chair

Stephan Grupp, MD, PhD
University of Pennsylvania

Co-Chair

Marcela V. Maus, MD, PhD
Massachusetts General Hospital

Return to ...